Axoltis Pharma has closed an €18 million Series A round to accelerate development of NX210c, its Phase 2 neurodegenerative-disease candidate for Amyotrophic Lateral Sclerosis (ALS). The raise will be deployed in two tranches, with the second contingent on Phase 2 SEALS trial results expected in Q2 2026.
FIDAT Ventures and Cenitz co-led the round, joined by a broad combination of private investors, business angels, and participants from a Capital Cell equity-crowdfunding campaign. Agile Capital Market advised the transaction and introduced key investors. Legacy backers—including Norfoalk, FRAI AURA (advised by UI Investissement), FaDièse 3, Simba Santé 2 (Angelor), and multiple historic angels—also participated, along with Axoltis’ CEO.
Funds will support continued clinical development of NX210c, a cyclic peptide designed to repair the blood-brain barrier and improve neurological function. The ongoing Phase 2 SEALS trial is evaluating efficacy and tolerability in 82 ALS patients across 16 sites. Enrollment was completed in mid-November.
Axoltis will also use the capital to explore NX210c’s applicability across additional neurological indications where blood-brain barrier repair could provide therapeutic benefit. The company plans to continue partnership discussions with global pharmaceutical companies and will participate in the 2026 J.P. Morgan Healthcare Conference.
KEY QUOTES:
“At a time when biotech funding remains particularly challenging, the success of this round demonstrates that investors believe in our strategy.”
“This fundraising allows us to maintain our head start… and continue discussions with world-class pharmaceutical companies toward a global partnership.”
Yann Godfrin, CEO, Axoltis Pharma
“The enthusiasm, perseverance and resilience demonstrated by the Axoltis team over the last few months are exceptional in the current financial climate.”
Dr. Gilles Avenard, Chairman of the Supervisory Board
“Axoltis Pharma combines a high-performance team, a distinctive technology and remarkable development potential.”
Frédéric Picq, Co-Founder and Partner, Cenitz
“Axoltis is developing a breakthrough treatment that could change the lives of millions of patients… a win-win situation for society as a whole.”
Daniel Oliver Uriel, Founder & CEO, Capital Cell
